中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (6): 459-462.doi: 10.19401/j.cnki.1007-3639.2017.06.010

• 专家述评与论著 • 上一篇    下一篇

头颈部肿瘤的免疫治疗

郭 晔   

  1. 复旦大学附属肿瘤医院肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2017-06-30 发布日期:2017-07-26
  • 通信作者: 郭 晔 E-mail: pattrickguo@gmail.com

The immunotherapy for head and neck cancer

GUO Ye   

  1. Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2017-06-30 Online:2017-07-26
  • Contact: GUO Ye E-mail: pattrickguo@gmail.com

摘要: 头颈部鳞癌(head and neck squamous cell carcinoma,HNSCC)是头颈部肿瘤的常见类型,其治疗水平有待提高。作为一种具有高度免疫缺陷的肿瘤,HNSCC主要机制包括免疫耐受的导入、局部的免疫逃逸和T细胞信号的破坏。免疫检查点是T细胞功能的重要决定因素,目前针对程序性细胞死亡1受体(programmed cell death 1,PD-1)的抑制剂得到了快速的发展。作为人源化的抗PD-1单克隆抗体,pembrolizumab和nivolumab均显示出针对复发或转移性HNSCC具有一定的解救治疗作用,进一步的研究值得期待。

关键词: 头颈部鳞癌, 免疫治疗, 免疫检查点抑制剂

Abstract: The predominant type of head and neck cancer is head and neck squamous cell carcinoma (HNSCC), which needs more effective treatment. As a highly immunosuppressive malignancy, HNSCC has 3 major mechanisms including induction of immune tolerance, local immune evasion, and disruption of T-cell signaling. Immune checkpoint plays a critical role in the function of T-cell and rapid development has been achieved by inhibiting programmed cell death 1 (PD-1). As anti-PD1 humanized monoclonal antibodies, pembrolizumab and nivolumab have proven to be effective in the salvage treatment for recurrent or metastatic HNSCC, further investigation is awaited.

Key words: Head and neck squamous cell carcinoma, Immunotherapy, Immune checkpoint inhibitor